Lv5
830 积分 2023-04-18 加入
司美格鲁肽治疗早发2型糖尿病的真实世界研究
3天前
已完结
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist
5天前
已完结
43RD ANNUAL MEETING OF THE OBESITY SOCIETY AT OBESITYWEEK® Poster Abstracts
5天前
已关闭
43RD ANNUAL MEETING OF THE OBESITY SOCIETY AT OBESITYWEEK® Oral Abstracts
5天前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
5天前
已完结
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial
6天前
已关闭
Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial
6天前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
6天前
已完结
Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement
6天前
已完结
Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types
8天前
已完结
皖公网安备34019202002308
